In a retrospective cohort study of 348 HER2‐positive breast cancer patients, of which 58.9% received neoadjuvant dual HER2‐targeted treatment, Wetzel et al. reported an overall discordance rate of 28%. Here, ERBB2 is linked to breast carcinoma.